Vancouver, BC – December 21, 2020
BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”) announced today that further analysis of the data from a preclinical animal study (also known as the “murine model study”) of its haptenized viral protein vaccine technology show that BVX-0320, its Covid-19 vaccine candidate based on the Company’s haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2.
Using a technique called flow cytometry, the BioVaxys team found that its haptenized SARS-CoV-2 s-spike vaccine activated CD4+ helper T cells and CD8+ killer T cells that express the activation markers, CD69 and CD25. This result indicates that immunization with BVX-0320 at two different dose levels of 3µg or 10µg stimulated immune system memory ‘helper’ T-cells as well as killer T cells. CD4
Share this article
VANCOUVER, British Columbia, Dec. 21, 2020 /CNW/ BioVaxys Technology Corp. (
CSE: BIOV, FRA:5LB, OTC:LMNGF) ( BioVaxys ) announced today that further analysis of the data from a preclinical animal study (also known as the murine model study ) of its haptenized viral protein vaccine technology show that BVX-0320, its COVID-19 vaccine candidate based on the Company s haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2.
Using a technique called flow cytometry, the BioVaxys team found that its haptenized SARS-CoV-2 s-spike vaccine activated CD4+ helper T cells and CD8+ killer T cells that express the activation markers, CD69 and CD25. This result indicates that immunization with BVX-0320 at two different dose levels of 3µg or 10µg stimulated immune system memory helper T-cells as well as killer T cells. CD4
BioVaxys Technology Corp : BioVaxys Announces Form 211 Clearance For OTC Trading in the USA finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.